Freedom Capital keeps Inspire Medical at Buy, cuts price target to $93
Freedom Capital Markets kept its Buy rating on Inspire Medical Systems and lowered its price target to $93 from $97, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Freedom Capital Markets retained its Buy recommendation on Inspire Medical Systems shares but trimmed its price target by 4.1%, from $97 to $93. TradingView reports this, citing data from Benzinga.
The new target implies 53.6% upside from the November 12 close of $60.54. Over the past 30 days, five other analyst notes set price targets between $60 and $76.
why it matters
For investors this is a routine update on a single medical technology company, so its effect on the broader market is limited. Targets like this reflect one firm's view and are best weighed alongside other, more cautious estimates.
tags
instruments
sources
- Freedom Capital Markets maintains Inspire Medical Systems at Buy, lowers price target to $93 from $97 — TradingView, 13 November 2026 at 19:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗